These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23 related articles for article (PubMed ID: 6661513)
1. Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. Lee JK; Paine MF; Brouwer KL J Pharmacol Exp Ther; 2010 Aug; 334(2):410-8. PubMed ID: 20430841 [TBL] [Abstract][Full Text] [Related]
2. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Friedman GD; Udaltsova N; Chan J; Quesenberry CP; Habel LA Cancer Causes Control; 2009 Dec; 20(10):1821-35. PubMed ID: 19582585 [TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of sulindac. A dynamic old drug. Davies NM; Watson MS Clin Pharmacokinet; 1997 Jun; 32(6):437-59. PubMed ID: 9195115 [TBL] [Abstract][Full Text] [Related]
4. Prodrugs. Do they have advantages in clinical practice? Stella VJ; Charman WN; Naringrekar VH Drugs; 1985 May; 29(5):455-73. PubMed ID: 3891303 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of drugs used in juvenile arthritis. Skeith KJ; Jamali F Clin Pharmacokinet; 1991 Aug; 21(2):129-49. PubMed ID: 1884567 [TBL] [Abstract][Full Text] [Related]
6. Biliary excretion of drugs in man. Rollins DE; Klaassen CD Clin Pharmacokinet; 1979; 4(5):368-79. PubMed ID: 389528 [TBL] [Abstract][Full Text] [Related]
8. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion. Lin JH; Yeh KC; Duggan DE Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112 [TBL] [Abstract][Full Text] [Related]